Finance

Beta
Lists
TCRX:NASDAQ
Tscan Therapeutics Inc
$1.07
+9.17%
(+0.090) 1D
$1.07
0.00% (0.00)
After hours
Closed: Jul 1, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TCRX...
Open
$0.99
High
$1.08
Low
$0.98
Mkt. cap
69.93M
Avg. vol.
552.93K
Volume
1.68M
52-wk high
$2.57
52-wk low
$0.83
EPS
-$0.96
Beta
1.03
Shares outstanding
61.07M
No. of employees
138
Open
$0.99
High
$1.08
Low
$0.98
Mkt. cap
69.93M
Avg. vol.
552.93K
Volume
1.68M
52-wk high
$2.57
52-wk low
$0.83
EPS
-$0.96
Beta
1.03
Shares outstanding
61.07M
No. of employees
138
News stories
From sources across the web
About Tscan Therapeutics Inc
CEO-
Employees138
Founded2018
HeadquartersWaltham, Massachusetts, United States
SectorBiotechnology
Websitetscan.com
Analyst ratings
Based on 5 analysts giving stock ratings to TCRX in the past 3 months
Strong buy
Buy
4
Hold
1
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for TCRX in the last 3 months.
Highest
Current $1.07
$7.00 (+554.21%)
Average
$6.00 (+460.75%)
Lowest
$5.00 (+367.29%)
Analyst
Recommendation
Action
Price target
Projected
Date
David Nierengarten
Wedbush
Buy
Maintained
$5.00
+367.3%
06/23/2026
Maxwell Skor
Morgan Stanley
Hold
Maintained
-
-
06/22/2026
Sam Slutsky
LifeSci Capital
Buy
Maintained
$6.00
+460.7%
06/23/2026
Gil Blum
Needham
Buy
Reiterated
$6.00
+460.7%
06/23/2026
Andres Y. Maldonado
H.C. Wainwright
Buy
Reiterated
$7.00
+554.2%
06/23/2026
Tara Bancroft
TD Cowen
Buy
Maintained
-
-
03/11/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
3.08M
2.51M
2.57M
982.00K
Cost of goods sold
32.63M
31.69M
18.44M
21.90M
Cost of revenue
32.63M
31.69M
18.44M
21.90M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
9.10M
7.87M
5.99M
8.22M
Operating expense
9.10M
7.87M
5.99M
8.22M
Total operating expenses
41.73M
39.56M
24.42M
30.12M
Operating income
-38.65M
-37.05M
-21.86M
-29.14M
Other non operating income
-
-
-
-
EBT including unusual items
-36.95M
-35.71M
-22.98M
-28.67M
EBT excluding unusual items
-36.95M
-35.71M
-20.98M
-28.67M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-36.95M
-35.71M
-22.98M
-28.67M
Net profit margin
-1,201.30%
-1,422.14%
-895.09%
-2,919.14%
Earnings per share
-0.28
-0.28
-0.18
-0.22
Interest and investment income
2.39M
2.04M
1.58M
1.16M
Interest expense
-689.00K
-699.00K
-702.00K
-689.00K
Net interest expenses
1.70M
1.34M
881.00K
473.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-37.96M
-36.28M
-21.14M
-28.45M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer